Barron's weekend stock picks: Eli Lilly, Activision and what's next for Tesla

Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. "Eli Lilly is riding the wave of weight loss. Why his dominance could last for years", by Jack Hough, explains why a promising obesity drug from Indiana-based Eli Lilly And Co LLY could give the company a major boost. In "The Microsoft saga of Activision is almost over. It may be time to sell the stock", Connor Smith warns investors against Activision Blizzard Inc's ATVI stock, especially amid the challenges facing the video game holding company faces in its potential acquisition by Microsoft Corp MSFT. In "Why SoFi Stock Is Falling After Supreme Court Rules Against Student-Loan Forgiveness," Emily Dattilo writes that the High Court's controversial decision to block President Joe Biden's plan to forgive student loans has had little effect on financial services firm SoFi Technologies Inc SOFI, which had seen student loans fall 47% year over year in its last quarter. "Apple is now worth $3 trillion. How its stock could rise another 30%," by Jack Denton, explains why some analysts believe the street is undervaluing tech giant Apple Inc's AAPL "further expansion gross margin". In "Tesla Stock Has Doubled This Year. What History Says Happens Next," Ben Levisohn examines how a number of stocks that doubled in the first half fared in the second half of each of the past five years, and what this could mean for Tesla Inc TSLA. Here's what that means for the financial services giant.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.